FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma
31 juil. 2023 06h00 HE | Invectys, Inc.
Houston, TX, USA, July 31, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company focused on developing novel therapies for advanced cancers, is pleased to announce the...
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
21 juil. 2023 09h09 HE | Incannex Healthcare
MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
18 juil. 2023 07h40 HE | Incannex Healthcare
Highlights: Incannex has engaged Fortrea as the contract research organisation (‘CRO’) to manage the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of OSA.The Phase 2/3...
Growth Report: Pre-Clinical CROs Market Worth $8.41 Billion, Worldwide Driven by Increasing Number of Clinical Trials During (2019-2027) | The Insight Partners
29 juin 2023 09h20 HE | The Insight Partners
Pune, India, June 29, 2023 (GLOBE NEWSWIRE) -- The Insight Partners’ latest study on "Pre Clinical CROs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by Service, End...
Low Loss Fill Process at Berkshire Sterile Manufacturing
Drug Product Filled with Berkshire Sterile’s Low Loss Fill Process Receives FDA Greenlight
18 mai 2023 13h00 HE | Berkshire Sterile Manufacturing
Lee, MA, May 18, 2023 (GLOBE NEWSWIRE) -- RNAimmune, a biotech company focused on developing groundbreaking mRNA therapies, recently received FDA approval to begin Phase 1 clinical studies for an...
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by EF Hutton with a “Buy” Recommendation
14 mars 2023 08h01 HE | Ocean Biomedical, Inc.
Providence, RI, March 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation of equity analyst coverage by EF Hutton with a...
Full Logo - OKYO .jpg
OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.
21 févr. 2023 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) (“OKYO”, “OKYO Pharma” or the “Company”), an ophthalmology-focused bio-pharmaceutical company...
Psycheceutical Bioscience Final Horiztonal Logo RGB.png
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
02 févr. 2023 10h20 HE | Psycheceutical Bioscience, Inc.
MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
26 janv. 2023 14h05 HE | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Kura Oncology Logo
Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
24 janv. 2023 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...